•   0 Comments       0 Like

What Is Rasmussen’s Syndrome and How Can It Cause Repeated Seizures?

The human cerebral cortex relies on a delicate equilibrium between excitatory glutamatergic signaling and inhibitory gamma-aminobutyric acid (GABA) modulation to execute motor control, sensory processing, and cognitive integration without uncontrolled electrical discharges. When chronic focal inflammation disrupts this cortical homeostasis, localized neuronal networks become hyperexcitable, generating recurrent, self-sustaining epileptic seizures. Rasmussen’s Syndrome—clinically designated as Rasmussen’s encephalitis—is a rare, progressive, chronic neurological disorder characterized by severe, drug-resistant focal epilepsy, progressive hemiplegia, and cognitive decline resulting from immune-mediated inflammation restricted almost exclusively to a single cerebral hemisphere. Primarily affecting children between the ages of two and ten years, with rare adolescent or adult-onset variants, the condition follows a relentless clinical trajectory marked by relentless motor seizures and progressive cortical atrophy. Understanding how localized neuroinflammation triggers intractable seizure activity requires analyzing its cellular immunopathology, excitotoxic mechanisms, electrophysiological hallmarks, and radical surgical interventions.

Immunopathological Foundations and T-Cell Mediated Neurodegeneration

Although early investigators suspected a chronic viral infection as the primary etiology of Rasmussen’s syndrome, exhaustive histopathological and molecular studies have established that the disorder is driven predominantly by an adaptive, cell-mediated autoimmune attack against central nervous system parenchyma. Brain biopsies obtained from affected cortical regions demonstrate classic hallmarks of chronic encephalitis, including perivascular lymphocytic cuffing, widespread microglial activation, reactive astrogliosis, and progressive neuronal dropout. Immunohistochemical profiling reveals that the inflammatory infiltrate consists largely of clonally expanded cytotoxic CD8-positive T-lymphocytes juxtaposed directly against neurons and astrocytes. These activated CD8-positive T-cells release cytolytic granules containing granzyme B and perforin directly onto target neural membranes, inducing programmed cell death. Concurrently, resident microglia become hyperactivated, secreting pro-inflammatory cytokines such as interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma, which disrupt blood-brain barrier integrity and recruit additional peripheral immune cells into the affected hemisphere.

Molecular Mechanisms of Cortical Hyperexcitability and Epileptogenesis

The relentless seizure activity observed in Rasmussen’s syndrome stems directly from the structural and biochemical disruption caused by chronic cytotoxic neuroinflammation. As CD8-positive T-cells and activated microglia destroy cortical neurons, inhibitory GABAergic interneurons appear disproportionately vulnerable to inflammatory injury, stripping cortical microcircuits of their physiological braking mechanisms. Simultaneously, pro-inflammatory cytokines released by reactive astrocytes and microglia impair astrocytic glutamate transporters—specifically excitatory amino acid transporter 2 (EAAT2)—preventing the clearance of excess glutamate from the synaptic cleft. Elevated extracellular glutamate overstimulates N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, triggering massive calcium influx into surviving pyramidal neurons. This cascade produces profound membrane depolarization, paroxysmal depolarization shifts, and synchronous hyperexcitable firing across neighboring cortical columns. Over time, repeated seizure discharges induce excitotoxic neuronal necrosis, creating an epileptic network that propagates electrical instability throughout the entire affected cerebral hemisphere while leaving the contralateral hemisphere structurally spared.

Clinical Progression and Epilepsia Partialis Continua

The clinical course of Rasmussen’s syndrome unfolds across three distinct stages: a prodromal phase, an acute phase, and a residual phase. During the prodromal stage, patients experience infrequent focal motor or generalized seizures alongside mild, subtle unilateral motor weakness that may persist for several months before diagnostic clarity emerges. Transitioning into the acute phase, seizure frequency escalates dramatically, culminating in the hallmark clinical manifestation of the disorder: Epilepsia Partialis Continua (EPC). Epilepsia partialis continua is a form of focal motor status epilepticus characterized by continuous, rhythmic, involuntary clonic jerking of isolated muscle groups—most commonly involving the contralateral face, distal hand, or arm—that persists uninterrupted for hours, days, weeks, or even years, remaining refractory to conventional antiepileptic drugs and persisting even during sleep. As inflammatory cortical destruction advances during the acute phase, patients develop progressive fixed neurological deficits, including dense spastic hemiparesis, homonymous hemianopsia, and severe aphasia when the language-dominant hemisphere is affected. Eventually, the disease enters a residual stage characterized by burnt-out inflammation, profound hemispheric atrophy, permanent neurological deficits, and persistent, albeit less frequent, seizures.

Diagnostic Neuroimaging and Electrophysiological Criteria

Establishing an early, accurate diagnosis of Rasmussen’s syndrome relies on correlating clinical progression with serial neuroimaging and electroencephalographic monitoring. Sequential Magnetic Resonance Imaging (MRI) of the brain demonstrates a characteristic unilateral evolution: early scans reveal focal cortical swelling and hyperintense signal abnormalities on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences, predominantly localized within the perisylvian region, insula, and frontotemporal cortex. Over subsequent months, serial MRI examinations document progressive, asymmetric volume loss of the affected hemisphere, marked by widening of cortical sulci, enlargement of the ipsilateral lateral ventricle, and distinctive atrophy of the ipsilateral caudate head. Electroencephalography (EEG) typically demonstrates polymorphic delta slowing over the inflamed hemisphere, multifocal interictal epileptiform spikes, and continuous ictal discharges, though surface EEG recordings frequently fail to capture clear rhythmic correlates during episodes of epilepsia partialis continua due to the small cortical generator volume. When neuroimaging and clinical features remain inconclusive, stereotactic brain biopsy confirming T-cell-dominated encephalitis and microglial nodules provides definitive histopathological verification.

Therapeutic Challenges: Immunomodulation Versus Functional Hemispherectomy

Managing Rasmussen’s syndrome poses substantial clinical challenges because conventional anti-seizure medications—including sodium channel blockers, benzodiazepines, and synaptic vesicle protein ligands—uniformly fail to halt epilepsia partialis continua or prevent underlying neurodegeneration. Immunomodulatory therapies—such as high-dose intravenous corticosteroids, intravenous immunoglobulins (IVIG), plasmapheresis, tacrolimus, and rituximab—can temporarily attenuate T-cell-mediated inflammation, slow motor decline, and reduce seizure burden during early stages, but they rarely achieve durable seizure freedom. Consequently, surgical disconnection of the affected cerebral hemisphere remains the only definitive curative treatment for intractable epilepsy in Rasmussen’s syndrome. Modern surgical intervention utilizes Functional Hemispherectomy (or hemispherotomy), a technique that removes a small central block of brain tissue while surgically severing all white matter projection fibers, commissural tracts, and corpus callosum pathways connecting the diseased hemisphere to the brainstem and healthy contralateral hemisphere. By isolating the epileptic hemisphere while leaving its vascular supply intact, functional hemispherectomy eliminates seizure propagation entirely in seventy to eighty percent of patients, allowing the healthy contralateral hemisphere to assume reorganized motor andcognitive functions via neuroplasticity.

Conclusion

Rasmussen’s syndrome is a devastating, progressive neurological disorder defined by unilateral cytotoxic T-lymphocyte encephalitis, relentless cortical atrophy, and drug-resistant focal epilepsy. Understanding how CD8-positive T-cell-mediated neuronal injury, impaired astrocytic glutamate clearance, and loss of GABAergic inhibition interact clarifies the emergence of continuous focal motor seizures and epilepsia partialis continua. Utilizing serial brain magnetic resonance imaging to track progressive hemispheric and caudate atrophy alongside electroencephalography enables clinical teams to diagnose the condition promptly before irreversible cognitive decline occurs. While early immunomodulatory regimens help stabilize acute neuroinflammation, timely functional hemispherectomy remains the definitive intervention capable of halting intractable seizure propagation, preserving contralateral hemispheric plasticity, and restoring long-term developmental potential for affected individuals.

0 Like

0 Comments

Leave a Reply

Required fields are marked *